Biotechnology in Lausanne: the Rh D project.

Details

Serval ID
serval:BIB_F58EC427315F
Type
Article: article from journal or magazin.
Collection
Publications
Title
Biotechnology in Lausanne: the Rh D project.
Journal
Chimia
Author(s)
Von Stockar U., Kragten E., Marison I.W., Amstutz H., Miescher S., Fisch I., Mermod N., DeJesus M., Freitag R., Wurm F.
ISSN
0009-4293
Publication state
Published
Issued date
1999
Peer-reviewed
Oui
Volume
53
Number
11
Pages
554-557
Language
english
Abstract
Hemolytic disease of the newborn is an often fatal condition of some newborn babies due to the immunogenicity of their Rh D positive erythrocytes in the Rh D negative mother. This condition can be prevented by injecting anti-Rh D antibodies. The current source of these antibodies is blood from immunized human donors. In order to avoid problems with limited supply and donor safety, the Rh D project was set up to develop recombinant monoclonal anti-Rh D antibodies as a possible replacement. In a multidisciplinary collaboration between the Zentrallaboratorium Blutspendedienst (ZlB) of the Swiss Red Cross, the Center of Biotechnology of the University and the EPFL (CBUE), and the Institute of Chemical and Biochemical Engineering (EPFl), co-funded by the Swiss National Science Foundation and ZLB, a candidate monoclonal anti-Rh D antibody has been selected, expressed in CHO cells, and a manufacturing process for large-scale production has been developed.
Web of science
Create date
20/03/2008 13:12
Last modification date
20/08/2019 17:22
Usage data